Fig. 1: Survival times in the RASwt population (n = 400).
Progression-free (a) and overall (b) survival in the RAS wild-type population (N = 400). Bev bevacizumab, Cet cetuximab.
Fig. 1: Survival times in the RASwt population (n = 400). | British Journal of Cancer
